- Home
- INKT vs ENLV Comparison
INKT vs ENLV Comparison
Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 196.2M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | INKT | ENLV |
|---|---|---|
| Price | $11.10 | $0.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $20.00 |
| AVG Volume (30 Days) | 23.9K | ★ 236.1K |
| Earning Date | 05-15-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $0.66 |
| 52 Week High | $76.00 | $2.10 |
Technical Indicators
Market Signals| Indicator | INKT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 35.04 |
| Support Level | $10.79 | $0.66 |
| Resistance Level | $12.40 | $1.25 |
| Average True Range (ATR) | 0.75 | 0.05 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 54.26 | 16.31 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.